AVU0 Stock Overview
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.80 |
52 Week High | US$27.80 |
52 Week Low | US$6.60 |
Beta | 0.79 |
1 Month Change | 0% |
3 Month Change | 81.60% |
1 Year Change | 102.74% |
3 Year Change | -82.17% |
5 Year Change | -74.20% |
Change since IPO | -91.95% |
Recent News & Updates
Recent updates
Shareholder Returns
AVU0 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -1.2% | 1.7% |
1Y | 102.7% | -23.0% | 2.3% |
Return vs Industry: AVU0 exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: AVU0 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
AVU0 volatility | |
---|---|
AVU0 Average Weekly Movement | 29.6% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AVU0's share price has been volatile over the past 3 months.
Volatility Over Time: AVU0's weekly volatility has increased from 17% to 30% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
AVU0 fundamental statistics | |
---|---|
Market cap | €213.65m |
Earnings (TTM) | -€109.64m |
Revenue (TTM) | €3.37m |
58.7x
P/S Ratio-1.8x
P/E RatioIs AVU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVU0 income statement (TTM) | |
---|---|
Revenue | US$3.60m |
Cost of Revenue | US$77.68m |
Gross Profit | -US$74.08m |
Other Expenses | US$43.09m |
Earnings | -US$117.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.65 |
Gross Margin | -2,057.67% |
Net Profit Margin | -3,254.58% |
Debt/Equity Ratio | 0% |
How did AVU0 perform over the long term?
See historical performance and comparison